These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 34213123)
1. [Determination of the anticoagulant activity of low molecular weight heparins by micellar electrokinetic chromatography combined with on-column enzymatic reaction]. Zhang M; Kang J Se Pu; 2020 Oct; 38(10):1243-1248. PubMed ID: 34213123 [TBL] [Abstract][Full Text] [Related]
2. [Determination of sulfation degree of heparin and low molecular weight heparins by capillary electrophoresis]. Shen Y; Kang J Se Pu; 2020 Oct; 38(10):1238-1242. PubMed ID: 34213122 [TBL] [Abstract][Full Text] [Related]
3. [An assay for anti-factor Xa activity of low molecular weight heparins by high performance liquid size exclusion chromatography]. Zhang Q; Kang J Se Pu; 2013 Jul; 31(7):684-90. PubMed ID: 24164039 [TBL] [Abstract][Full Text] [Related]
4. An update on heparins at the beginning of the new millennium. Fareed J; Hoppensteadt DA; Bick RL Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802 [TBL] [Abstract][Full Text] [Related]
5. Management of thrombotic and cardiovascular disorders in the new millenium. Fareed J; Hoppensteadt DA; Bick RL Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377 [TBL] [Abstract][Full Text] [Related]
6. Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs. Castro-López V; Harris LF; O'Donnell JS; Killard AJ Anal Bioanal Chem; 2011 Jan; 399(2):691-700. PubMed ID: 20972772 [TBL] [Abstract][Full Text] [Related]
7. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680 [TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders. Mousa SA Semin Thromb Hemost; 2000; 26 Suppl 1():39-46. PubMed ID: 11011805 [TBL] [Abstract][Full Text] [Related]
9. [Evaluation of anticoagulant activity for low molecular-weight heparin by chromogenic substrate. Measurement of factor Xa and thrombin activities]. Ishimitsu S; Sugiyama T; Itoh M; Natsuga T; Komatsu H; Okada S Yakugaku Zasshi; 1994 Aug; 114(8):611-7. PubMed ID: 7932105 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays. Harris LF; O'Brien A; Castro-López V; O'Donnell JS; Killard AJ Thromb Res; 2011 Dec; 128(6):e166-70. PubMed ID: 21872908 [TBL] [Abstract][Full Text] [Related]
11. Influence of different anticoagulant agents on fibrinopeptide a generation. Tobu M; Iqbal O; Messmore HL; Ma Q; Hoppensteadt DA; Fareed J Clin Appl Thromb Hemost; 2003 Oct; 9(4):273-92. PubMed ID: 14653437 [TBL] [Abstract][Full Text] [Related]
12. Feasibility study of heparin mass calibrator as a GPC calibrator for heparins and low molecular weight heparins. Ahsan A; Jeske W; Mardiguian J; Fareed J J Pharm Sci; 1994 Feb; 83(2):197-201. PubMed ID: 8169788 [TBL] [Abstract][Full Text] [Related]
13. Low-molecular-weight heparins in thrombosis and cancer: emerging links. Mousa SA Cardiovasc Drug Rev; 2004; 22(2):121-34. PubMed ID: 15179449 [TBL] [Abstract][Full Text] [Related]
15. Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review. Yan Y; Ji Y; Su N; Mei X; Wang Y; Du S; Zhu W; Zhang C; Lu Y; Xing XH Carbohydr Polym; 2017 Mar; 160():71-81. PubMed ID: 28115102 [TBL] [Abstract][Full Text] [Related]
16. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis? Boneu B Thromb Res; 2000 Oct; 100(2):V113-20. PubMed ID: 11053624 [TBL] [Abstract][Full Text] [Related]
17. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Andrassy K; Eschenfelder V Thromb Res; 1996; 81(2 Suppl):S29-38. PubMed ID: 8822125 [TBL] [Abstract][Full Text] [Related]
18. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood. Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227 [TBL] [Abstract][Full Text] [Related]
19. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma. Dempfle CE; Zharkowa U; Elmas E; Ahmad-Nejad P; Neumaier M; Borggrefe M Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540 [TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis. Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]